The role of molecular markers in predicting response to therapy in patients with colorectal cancer.

Molecular Diagnosis & Therapy
Veena ShankaranAl B Benson

Abstract

Advances in systemic therapy for colorectal cancer have dramatically improved prognosis. While disease stage has traditionally been the main determinant of disease course, several molecular characteristics of tumor specimens have recently been shown to have prognostic significance. Although to date no molecular characteristics have emerged as consistent predictors of response to therapy, retrospective studies have investigated the role of a variety of biomarkers, including microsatellite instability, loss of heterozygosity of 18q, type II transforming growth factor beta receptor, thymidylate synthase, epidermal growth factor receptor, and Kirsten-ras (KRAS). This paper reviews the current literature, ongoing prospective studies evaluating the role of these markers, and novel techniques such as gene profiling, which may help to uncover the more complex molecular interactions that will predict response to chemotherapy in patients with colorectal cancer.

References

Feb 8, 1990·The New England Journal of Medicine·C G MoertelJ H Glick
Jul 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·L LeichmanA Ortega
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A BeckG Milano
Dec 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P G JohnstonC J Allegra
Jul 28, 1994·The New England Journal of Medicine·J JenS R Hamilton
May 7, 1993·Science·L A AaltonenS R Hamilton
May 7, 1993·Science·S N ThibodeauD Schaid
May 20, 1998·Journal of the National Cancer Institute·H J AndreyevP A Clarke
Jan 1, 1999·Nature·C LengauerB Vogelstein
Jun 26, 1999·Gastroenterology·J M CarethersC R Boland
Jan 13, 2000·The New England Journal of Medicine·R GryfeS Gallinger
Apr 20, 2001·The New England Journal of Medicine·T WatanabeS R Hamilton
Sep 5, 2001·British Journal of Cancer·H J AndreyevN Urosevic
Dec 18, 2001·The Journal of Pathology·G GnanasampanthanB Iacopetta
Mar 2, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D C CorsiC Barone
Mar 29, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David EdlerHenric Blomgren
Apr 24, 2002·Best Practice & Research. Clinical Gastroenterology·Boris PascheAl B Benson
Nov 9, 2002·Lancet·P L BarrattUNKNOWN UKCCCR AXIS trial collaborators. Adjuvant X-ray and Fluorouracil Infusion Study
Mar 7, 2003·The New England Journal of Medicine·Henry T Lynch, Albert de la Chapelle
May 10, 2003·Hematology/oncology Clinics of North America·John M MariadasonDiego Arango
Sep 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wen-Kai Weng, Ronald Levy
Dec 6, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe TournigandAimery de Gramont
Feb 6, 2004·Gastroenterology·John M CarethersC Richard Boland
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B SaltzRobert J Mayer
Mar 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yixin WangDavid Atkins
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Jun 4, 2004·The New England Journal of Medicine·Thierry AndréUNKNOWN Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC)
Jul 23, 2004·The New England Journal of Medicine·David CunninghamEric Van Cutsem
Nov 13, 2004·CA: a Cancer Journal for Clinicians·Carolyn C Compton, Frederick L Greene
Nov 25, 2004·The Oncologist·Mary Cianfrocca, Lori J Goldstein
Jan 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S PopatR S Houlston
Apr 27, 2005·The Oncologist·Lisa Baddi, Al Benson
May 24, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Steven EschrichTimothy J Yeatman
Jul 9, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wendy L Allen, Patrick G Johnston
Nov 25, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J Y Douillard, J Bennouna

❮ Previous
Next ❯

Citations

Jun 30, 2010·The Oncologist·Vanessa DeschoolmeesterJan B Vermorken
Feb 18, 2009·International Journal of Colorectal Disease·Emmanuel MitryPhilippe Rougier
Jun 1, 2012·Expert Opinion on Drug Discovery·Nagasuma Chandra
Aug 19, 2010·American Journal of Clinical Pathology·Jeffrey S RossDavid M Jones
Aug 24, 2011·Clinical Colorectal Cancer·Robin K Kelley, Alan P Venook
Jan 27, 2010·Clinical Colorectal Cancer·Marwan M Fakih
Jan 3, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·David EdlerPeter Ragnhammar
May 17, 2011·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Michael D'AngelicaJinru Shia
Jun 11, 2011·Biomarkers in Medicine·Jeffrey S Ross
Jan 21, 2009·Nature Clinical Practice. Gastroenterology & Hepatology·Rachel S MidgleyDavid J Kerr
Aug 18, 2009·The Oncologist·Meredith K ChukElizabeth Fox

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.